Carregant...
Decade in review: a new era for RET-rearranged lung cancers
Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global burden of disease. Although these fusions were first...
Guardat en:
| Publicat a: | Transl Lung Cancer Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7815364/ https://ncbi.nlm.nih.gov/pubmed/33489819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-346 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|